SELLAS Life Sciences Group is a New York late-stage oncology company whose equity now prices a registrational acute myeloid leukemia franchise as if the blinded Phase Three survival study is already leaning positive. Galinpepimut-S, a Wilms tumor 1 peptide vaccine licensed from Memorial Sloan Kettering, is the load-bearing asset. Tambiciclib, a selective cyclin-dependent kinase nine inhibitor licensed from GenFleet, is the second program and is already in a frontline randomized study. The investment debate is whether the current capitalization is paying for a high-probability registrational win or for a still-unproven survival signal plus an earlier-stage option.
The tension sits in the event clock, not in the income statement. An independent data committee already allowed the REGAL maintenance study to continue after 60 deaths. The contract research organization last counted 78 events in May, and that tally had not moved by the August update. Slower event accrual can mean patients are living longer, which is the constructive read, or it can mean the remaining deaths simply have not been reported. Warrant exercises rebuilt the cash box and left the unused at-the-market facility sitting as dry powder. The share count roughly doubled from the year-ago quarter, so the fortress was purchased with dilution at crisis-era strikes.
The quarter itself is a placeholder print. Operating spend rose as the company prepared a potential biologics license application, and a Hong Kong arbitrator dismissed the Greater China milestone claims. Cash now covers more than a year of planned operations at the current burn. What the next several months resolve is whether the eightieth death arrives with a survival curve that justifies a multi-billion enterprise value, or whether the market has prepaid for an outcome the blinded dataset does not support.